Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
NCT02582879 · View on ClinicalTrials.gov ↗
Study Summary
The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (PRO) measures.
Conditions Studied
Study Locations (20)
California
- John Muir Health — Concord
- North County Oncology Medical Clinic — Oceanside
- Sansum Clinic — Santa Barbara
- St Joseph Heritage Healthcare — Santa Rosa
- Sansum Clinic — Solvang
- Gregory Smith, MD (Private Practice) — St. Helena
- Solano Hematology Oncology — Vallejo
Arizona
- Arizona Oncology Associates, PC - HAL — Glendale
- Arizona Oncology Associates, PC - HAL — Phoenix
- Arizona Oncology Associates, PC - HAL — Phoenix
- Arizona Oncology Associates, PC - HAL-Scottsdale — Tempe
Arkansas
- Mercy Research — Fort Smith
- Genesis Cancer Center — Hot Springs
- Clopton Clinic of Jonesboro, Inc. — Jonesboro
- CARTI - Central Arkansas Radiation Therapy Institute — Little Rock
Colorado
- Rocky Mountain Cancer Centers, LLP- Aurora — Aurora
- Rocky Mountain Cancer Centers, LLP- Boulder — Boulder
- Rocky Mountain Cancer Centers — Colorado Springs
Alabama
- Clearview Cancer Institute — Huntsville
- Northwest Alabama Cancer Center, PC — Muscle Shoals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-07-21 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582879
The ClinicalTrials.gov registry entry for NCT02582879 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 13 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02582879 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02582879 about?
NCT02582879 is a clinical study titled "informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia". The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient charac...
What is the current status of trial NCT02582879?
This trial is currently completed. The enrollment target is 1,504 participants. The study started on 2015-09. Estimated completion is 2021-07-21.
What conditions does trial NCT02582879 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02582879?
This trial is sponsored by Pharmacyclics, which has 13 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02582879 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.